<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2008-14-3-281-284</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1241</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИЯ ДЛЯ ВРАЧЕЙ</subject></subj-group></article-categories><title-group><article-title>Гипертрофия левого желудочка и блокаторы рецепторов к ангиотензину II. От исследований к практическим рекомендациям</article-title><trans-title-group xml:lang="en"><trans-title>Left ventricular hypertrophy
and angiotensin II receptor blockers. From clinical
studies to clinical guidelines</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov Federal Heart, Blood and Endocrinology Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2008</year></pub-date><volume>14</volume><issue>3</issue><fpage>281</fpage><lpage>284</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Конради
                 А., 2008</copyright-statement><copyright-year>2008</copyright-year><copyright-holder xml:lang="ru">Конради
                 А.</copyright-holder><copyright-holder xml:lang="en">Konradi
                 A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1241">https://htn.almazovcentre.ru/jour/article/view/1241</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Aabiti-Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10:288 298.</mixed-citation><mixed-citation xml:lang="en">Aabiti-Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10:288 298.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jennings G, Wong J. Regression of Left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis. J Hypertens Suppl 1998; 16:S29-S34.</mixed-citation><mixed-citation xml:lang="en">Jennings G, Wong J. Regression of Left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis. J Hypertens Suppl 1998; 16:S29-S34.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sen S., Tarazi R.C. Reversal of the myocardial hypertrophy and influence of the adrenergic system. Am J Physiol 1983; 244: H97-H101.</mixed-citation><mixed-citation xml:lang="en">Sen S., Tarazi R.C. Reversal of the myocardial hypertrophy and influence of the adrenergic system. Am J Physiol 1983; 244: H97-H101.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - A metanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cruickshank JM, Lewes J, Moore EV, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 17:85-90.</mixed-citation><mixed-citation xml:lang="en">Cruickshank JM, Lewes J, Moore EV, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens 1992; 17:85-90.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Schmeider RE, Martus P, Klingbeil A., Reversal of left ventricular hypertrophy: analysis of 412 published studies. Am J Hypertens 1994;7:25A.</mixed-citation><mixed-citation xml:lang="en">Schmeider RE, Martus P, Klingbeil A., Reversal of left ventricular hypertrophy: analysis of 412 published studies. Am J Hypertens 1994;7:25A.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Schmeider RE, Schilachi MP, Klingbeil A, Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998; 13:564-569.</mixed-citation><mixed-citation xml:lang="en">Schmeider RE, Schilachi MP, Klingbeil A, Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996) Nephrol Dial Transplant 1998; 13:564-569.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul;115(1):41-6.</mixed-citation><mixed-citation xml:lang="en">Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003 Jul;115(1):41-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof В., Himmelman A., Svensson A. Losartan potassium versus atenolol. A comparison of efficiacy, tolerability and effect on left ventricular morphology. Ibid 1995; 27:27-28.</mixed-citation><mixed-citation xml:lang="en">Dahlof В., Himmelman A., Svensson A. Losartan potassium versus atenolol. A comparison of efficiacy, tolerability and effect on left ventricular morphology. Ibid 1995; 27:27-28.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Malmqvist K., Kahan Т., Edner M. et al. Regression of left ventricular hypertrophy with irbesartan. J Hypertension 2001; 19:1167-1176.</mixed-citation><mixed-citation xml:lang="en">Malmqvist K., Kahan Т., Edner M. et al. Regression of left ventricular hypertrophy with irbesartan. J Hypertension 2001; 19:1167-1176.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cuspidi C., Muiesan M.L., Valagussa L. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.J Hypertens 2002;20(11):2293-2300.</mixed-citation><mixed-citation xml:lang="en">Cuspidi C., Muiesan M.L., Valagussa L. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.J Hypertens 2002;20(11):2293-2300.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Thurmann P, Kenedi P, Schimdt et al. Influence of angiotensin II antagonist Valsartan on Left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.</mixed-citation><mixed-citation xml:lang="en">Thurmann P, Kenedi P, Schimdt et al. Influence of angiotensin II antagonist Valsartan on Left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007 Aug 14;116(7):700-5.</mixed-citation><mixed-citation xml:lang="en">Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007 Aug 14;116(7):700-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Weber KT, Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991; 12:61-69.</mixed-citation><mixed-citation xml:lang="en">Weber KT, Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991; 12:61-69.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Varo N., Etayo J.C., Zalba G. et al. Losartan inhibits the post-transcriptional synthesis of collagen type 1 and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertension 1999; 17(1):107-114.</mixed-citation><mixed-citation xml:lang="en">Varo N., Etayo J.C., Zalba G. et al. Losartan inhibits the post-transcriptional synthesis of collagen type 1 and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertension 1999; 17(1):107-114.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Brown L., Fenning A., Shek A., Burtow D. Reversal of cardiovascular remodelling with candesartan. JRAAS 2001; 2(1): S141-S147.</mixed-citation><mixed-citation xml:lang="en">Brown L., Fenning A., Shek A., Burtow D. Reversal of cardiovascular remodelling with candesartan. JRAAS 2001; 2(1): S141-S147.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B. Agabiti-Rosei E, Zaliunas R. Et al. Improvement in left ventricular function following treatment of hypertension with omapatrilat vs losartan. Eur H J 2000; Abst Suppl. p 344 (A1847).</mixed-citation><mixed-citation xml:lang="en">Dahlof B. Agabiti-Rosei E, Zaliunas R. Et al. Improvement in left ventricular function following treatment of hypertension with omapatrilat vs losartan. Eur H J 2000; Abst Suppl. p 344 (A1847).</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
